Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 4.5% – What’s Next?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dropped 4.5% on Thursday . The stock traded as low as $0.31 and last traded at $0.32. Approximately 28,860,322 shares changed hands during mid-day trading, a decline of 7% from the average daily volume of 31,034,150 shares. The stock had previously closed at $0.33.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Wednesday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average price of $0.23 and a two-hundred day moving average price of $0.37. The stock has a market capitalization of $59.73 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. On average, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.